|
Apr 15
|
Acorda Therapeutics Announces Delisting from Nasdaq
|
|
Apr 6
|
Riskiest Junk Bonds Shunned in Europe on Rising Risk of Default
|
|
Apr 3
|
Acorda Therapeutics Announces Nasdaq Delisting Notification
|
|
Apr 2
|
Acorda files for bankruptcy, reveals asset sale plan
|
|
Apr 1
|
Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement
|
|
Apr 1
|
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
|
|
Mar 25
|
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
|
|
Jan 11
|
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
|
|
Dec 18
|
Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Shares Bounce 53% But Its Business Still Trails The Industry
|
|
Nov 13
|
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
|
|
Nov 6
|
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
|
|
Nov 6
|
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
|
|
Aug 8
|
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
|
|
Jun 28
|
Tom Burns Elected to the Acorda Therapeutics Board of Directors
|
|
Jun 26
|
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
|